Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

In some MM hospitals in China they offer NK cell infusions, but it’s not cheap, maybe more expensive than Dara and also for CD38 knockout NK cells, I think it’s a technique only for clinical trials in MM sadly.
If CD38- nk cells does prove to be the reason for response/non response then F&M are probably well placed to evaluage whether these infusions could be viable in MECFS patients, given their expertise in oncology.
 
Then the question is how to boost cd38- NK cells. I see some literature on IL2 (Evren Alicis paper cultured NK cells in ex vivo il2 and found the cd38 expression dropped drastically in the expanded pool). They were surprised and used this cell line in MM trials.

I contacted some leading MM researchers to ask and they all laughed me out of the park lol.

TA1 boosts IL2 receptors on NK cells.

@jnmaciuch any ideas?
 
Sorry to hear you had no response. That is quite interesting about your drastic NK cell drop maybe being to do with not having cd38- NK cells.

But perhaps people with naturally higher overall NK cells do have higher cd38- nk cells. I'm not sure we can conclude responses are likely to be low in the trial from what you've set out here.

I wonder if isatuximab will prove more or less effective than dara. Not got the spoons to read through it right now but here's something about isa mechanism of action


Yeah sadly, but given the late responses 4-5 months of the partial responders… maybe for some reason in men the response comes later? But then again, I don’t see any reason why gender would affect response timing.

@jnmaciuch
 
Back
Top Bottom